3. Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene. 2007;26:6766–76.
4. Calvo KR, Sykes DB, Pasillas MP, Kamps MP. Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1. Oncogene. 2002;21:4247–56.
5. Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J. 2001;20:350–61.
6. Iwasaki M, Kuwata T, Yamazaki Y, et al. Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model. Blood. 2005;105:784–93.
7. Maki K, Yamagata T, Mitani K. Role of the *RUNX1-EVI1* fusion gene in leukemogenesis. Cancer Sci. 2008;99:1878–83.
8. Vinatzer U, Mannhalter C, Mitterbauer M, et al. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. Genes Chromosomes Cancer. 2003;36:80–9.
9. Morishita K. Leukemogenesis of the EVI1/MEL1 gene family. Leukemogenesis of the EVI1/MEL1 gene family. Int J Hematol. 2007;85:279–86.
10. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 2003;101:837–45.
11. Takeda A, Goolsby C, Yaseen NR. NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34 + hematopoietic cells. Cancer Res. 2006;66:6628–37.
12. Palmqvist L, Argiropoulos B, Pineault N, et al. The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia. Blood. 2006;108:1030–6.
13. Jankovic D, Gorello P, Liu T, et al. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia. Blood. 2008;111:5672–82.

Int J Hematol (2009) 90:91–93
DOI 10.1007/s12185-009-0336-z

CASE REPORT

Presentation of familial Mediterranean fever in a heterozygous *MEFV* mutation triggered by immunosuppressive therapy for myelodysplastic syndrome

Ko Sasaki · Toshiyuki Tahara · Kinuko Mitani

Received: 28 July 2008 / Revised: 18 February 2009 / Accepted: 22 April 2009 / Published online: 23 May 2009
© The Japanese Society of Hematology 2009

Abstract Familial Mediterranean fever (FMF) is a recessively inherited disease characterized by recurrent episodes of systemic inflammation. The cause of this disease is the mutations affecting both the alleles of *MEFV* gene. We describe here a case in a heterozygous *MEFV* mutation complicated with myelodysplastic syndrome (MDS). Clinical symptoms and the effectiveness of colchicines in this patient are typical for FMF. The first attack of FMF in this patient was observed during immunosuppressive therapy for MDS. This case suggests the possibility that certain immunosuppressants may trigger FMF attack in asymptomatic cases carrying *MEFV* heterozygous mutation.

Keywords Myelodysplastic syndrome · Familial Mediterranean fever · Immunosuppressive therapy · *MEFV* gene

1 Introduction

Familial Mediterranean fever (FMF) is a recessively inherited disease characterized by recurrent episodes of systemic inflammation and is observed in Mediterranean and Middle Eastern populations. Ninety percent of FMF patients have the first attack by the age of 20. Typical events include abdominal, pleural and arthritic attacks that generally last 24–72 h. The cause of this disease is the mutations affecting both the alleles of *MEFV* gene. *MEFV* gene mapped at 16p13.3 was isolated independently by two groups [1, 2]. So far, various kinds of mutations in *MEFV* gene have been reported. Most of the disease-associated mutations are located in exon 10 of the gene with the smaller group in exon 2. Five founder mutations including this patient's type V726A, M694V, M694I, M680I and E148Q account for 74% of typical FMF cases [3]. More severe symptoms of systemic inflammation with a higher incidence of systemic amyloidosis are usually associated with M694V homozygotes.

2 Case report

In May 1998, a 19-year-old male was hospitalized in a practitioner's institute because of pneumonia. He was introduced to our hospital because pancytopenia was pointed out during the hospitalization. On admission, he had slight fever. Laboratory studies disclosed pancytopenia and increased levels of non-specific parameter for inflammation. Histological examination revealed no evidence of proliferation of immature blasts but with abundant ringed sideroblast in the bone marrow (Table 1). Chromosomal analysis of bone marrow cells showed 46,XY,del. Above all, he was diagnosed as myelodysplastic syndrome (MDS) associated with isolated del(5q) chromosome abnormality according to the WHO classification, although ringed sideroblasts were observed up to >15% among erythroid progenitors. After the introduction of oral cyclosporine A

K. Sasaki · K. Mitani (✉)
Department of Hematology,
Dokkyo Medical University School of Medicine,
880 Kitakobayashi, Mibu-machi, Shimotsuga-gun,
Tochigi 321-0293, Japan
e-mail: kinukom-tky@umin.ac.jp;
mitanik@dokkyomed.ac.jp

T. Tahara
Department of Gastroenterology,
Saiseikai Utsunomiya Hospital,
911-1 Takebayashi, Utsunomiya,
Tochigi 321-097, Japan
e-mail: toshiyuki_tahara@saimiya.com

(CsA) at a dose of 300 mg/day, pancytopenia was dissolved. However, administration of CsA at a dose of 50 mg/day was required to maintain complete hematological response. In 2007, he suddenly presented an abdominal pain with fever of 38°C or higher and diarrhea that lasted within 24 h. And this attack recurred afterward. His clinical course satisfied the diagnostic criteria for FMF [4]. His disease severity score was more than 4 (The presence of amyloidosis had not been checked.). His severity score was low in comparison with the mean score in both Iraqi Jews (6.25) and North Africans (9.24) [5]. A consulted physician of digestive tract internal medicine sought for mutation in the Mediterranean fever (*MEFV*) gene responsible for FMF. The sequence analysis was performed about whole coding regions of *MEFV* gene except exon 2. As a result, ATG of codon 694 in exon 10 was shown to be substituted to ATA in the single allele, indicating heterozygous mutation of *MEFV* gene (M694I). Even after the diagnosis of FMF, immunosuppressive therapy for MDS was not changed, and colchicines therapies were started in use to hang around. Colchicines therapies were very effective, and the symptoms of inflammation fever and abdominal pain were improved after the administration of colchicines.

Table 1 Laboratory findings on admission

Peripheral blood	
WBC	4300/μL
Stab.	0%
Seg.	74.0%
Eosino.	0%
Baso.	0%
Mono.	4.0%
Lymph.	19.0%
Atypical Ly	3.0%
RBC	220 × 10^4/μL
Hb	8.4 g/dl
Ht	23.4%
MCV	106.0 fl
HCH	38.0 pg
MCHC	35.9%
PLT	2.3 × 10^4/μL
Reti.	5‰
Biochemistry	
TP	6.6 g/dL
Alb	3.6 g/dL
T. Bil	1.1 mg/dL
D. Bil	0.4 mg/dL
I. Bil	0.7 mg/dL
AST	90 IU/L
ALS	165 IU/L
ALP	193 IU/L
γ-GTP	54 IU/L
LDH	769 IU/L
BUN	15 mg/dL
Cr	0.9 mg/dL
Na	137 mEq/L
K	4.1 mEq/L
Cl	103 mEq/L
UA	4.0 mg/dL
CRP	4.6 mg/dL
Bone marrow	
NCC	16.2 × 10^4/μl
Mgk	15/μl
Mbl	0.6%
Promyelo.	1.4%
Myelo.	8.4%
Meta.	11.2%
Stab.	20.4%
Seg.	20.0%
Eosino.	0.4%
Baso.	0%
Mono.	3.6%
Lymph.	9.2%
Plasma	0.6%
Ebl baso.	1.6%
poly.	20.2%
orth.	2.4%
Iron stain	
Ringed sideroblasts	27%/Ebl
Chromosome (Bone marrow)	
46,XY,del(9)	5/20

3 Discussion

All the patients with FMF do not necessarily conform to a recessive mode of inheritance. In the cases of heterozygous carriers, it is possible that various inflammatory stimuli predispose them to acute attacks of FMF [6]. One candidate inflammatory disease that may cause acute attacks in FMF heterozygotes is Behçet's disease. However, there was no symptom for Behçet's disease in this patient. The *MEFV* gene encoding pyrin (marenostine) is upregulated in response to inflammatory mediators [7] including TNF-α. On the other hand, CsA blocks the induction of TNF-α gene at a transcriptional level [8]. We thus speculated that this patient possibly had a reduced level of pyrin characterizing heterozygosity, and that administration of CsA further stressed the tendency through inhibiting TNF-α expression, which led to FMF attacks.

So far, direct evidence indicating that CsA suppresses the *MEFV* gene expression has not been reported. However, Khosroshahi [9] reported the FMF case that manifested the first attack during the immunosuppressive therapy after renal transplantation. The regimen of immunosuppressive therapy used for this case contained CsA. Therefore, this case indicates the possibility that CsA could trigger the first attack in FMF heterozygotes who are so far asymptomatic.

Here, we report a case of FMF patient carrying M694I heterozygous mutation of *MEFV* gene, whose first attack was presented during the course of immunosuppressive therapy for MDS. So far, no FMF cases complicated with MDS have been reported. This case suggests the possibility that certain immunosuppressants may cause attacks in cases carrying *MEFV* heterozygous mutation and also provides some warning for physicians to commence immunosuppressants for such patients.

References

1. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997;90(4):797–807. doi: 10.1016/S0092-8674(00)80539-5.
2. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25–31. doi:10.1038/ng0997-25.
3. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet. 2001;9(7):473–83. doi:10.1038/sj.ejhg.5200658.
4. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10):1879–85. doi:10.1002/art.1780401023.
5. Pras E, Livneh A, Balow JE Jr, Kastner DL, Pras M, Langevitz P. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet. 1998;75(2):216–9. doi:10.1002/(SICI)1096-8628(19980113)75:2<216::AID-AJMG20>3.0.CO;2-R.
6. Livneh A, Aksentijevich I, Langevitz P, Torosyan Y, GS N, Shinar Y, et al. A single mutated MEFV allele in Israeli patients suffering from familial Mediterranean fever and Behcet's disease (FMF-BD). Eur J Hum Genet. 2001;9(3):191–6. doi:10.1038/sj.ejhg.5200608.
7. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 2000;95(10):3223–31.
8. Goldfeld AE, McCaffrey PG, Strominger JL, Rao A. Identification of a novel cyclosporin-sensitive element in the human tumor necrosis factor alpha gene promoter. J Exp Med. 1993;178(4):1365–79. doi:10.1084/jem.178.4.1365.
9. Khosroshahi HT, Tubbs RS, Shoja MM. Familial Mediterranean fever triggered by renal transplantation. Nephrol Dial Transplant. 2006;21(10):3000–1. doi:10.1093/ndt/gfl282.

ASBMT
American Society for Blood and Marrow Transplantation

Clinical Significance of Serum Hepcidin Levels on Early Infectious Complications in Allogeneic Hematopoietic Stem Cell Transplantation

Junya Kanda,[1,3] Chisaki Mizumoto,[1] Hiroshi Kawabata,[1] Tatsuo Ichinohe,[1] Hideyuki Tsuchida,[2] Naohisa Tomosugi,[2] Keitaro Matsuo,[3,4] Kouhei Yamashita,[1] Tadakazu Kondo,[1] Takayuki Ishikawa,[1] Takashi Uchiyama[1]

The association of iron overload with complications of allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested in previous studies. Because hepcidin plays a central role in the regulation of iron homeostasis, we analyzed the association between pretransplant serum hepcidin-25 levels and early infectious complications after allogeneic HSCT. We studied 55 consecutive adult patients with a median age of 47 years (range: 20–64 years) who underwent allogeneic HSCT for hematologic malignancies at our institution. Thirty-two patients had myelogenous malignancies; the remaining 23 had lymphogenous malignancies. The median pretransplant serum hepcidin level of patients in the study was 21.6 ng/mL (range: 1.4–371 ng/mL), which was comparable to that of healthy volunteers (median: 19.1 ng/mL [range: 2.3–37 ng/mL]; n = 17). When cumulative incidences of documented bacterial and cytomegalovirus (CMV) infections at day 100 were compared according to pretransplant hepcidin-25 levels, the incidence of bacterial, but not CMV, infection, was significantly higher in the high-hepcidin group (≥50 ng/mL; n = 17) than in the low-hepcidin group (<50 ng/mL; n = 38) (65% [95% confidence interval, 38%–82%] versus 11% [3%–23%]; *P* <.001). This finding was confirmed by multivariate Cox analysis adjusted for confounders, including pretransplant ferritin and C-reactive protein (CRP) levels. No fungal infection was documented in either group. These results suggest that the pretransplant serum hepcidin-25 level may be a useful marker for predicting the risk of early bacterial complications after allogeneic HSCT. Larger prospective studies are, however, warranted to confirm our findings.

Biol Blood Marrow Transplant 15: 956-962 (2009) *© 2009 American Society for Blood and Marrow Transplantation*

KEY WORDS: Hepcidin, Bacterial infection, Allogeneic stem cell transplantation

INTRODUCTION

Allogeneic hematopoietic stem cell transplantation (HSCT) has been widely performed as a potentially curative treatment for intractable hematologic malignancies with conventional chemotherapy. However, despite recent advances in the treatment of infectious diseases and conditioning regimens for transplantation, treatment-related complications remain a major problem. Therefore, it is particularly important to identify a good biomarker that can predict treatment-related complications before transplantation. A recently accumulated body of evidence suggests that iron overload is associated with adverse clinical outcomes in HSCT [1-10]. Armand et al. [2] showed that a high pretransplant serum ferritin level was strongly associated with lower overall and disease-free survival (OS, DFS) in patients with allogeneic HSCT that was performed as a treatment for acute leukemia and myelodysplastic syndrome (MDS). Other studies have shown that pretransplant iron overload in autologous or allogeneic HSCT was a risk factor associated with posttransplant complications, such as mucositis, bacterial, and fungal infection, and hepatic veno-occlusive disease (VOD) [3-6,8-11].

Hepcidin, first identified in human blood and urine as an antimicrobial small peptide [12,13], is now considered to be a central molecule that regulates iron metabolism. Hepcidin decreases iron absorption from the intestine and blocks its release from iron stores by

From the [1]Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; [2]Proteomics Research Unit, Division of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan; [3]Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan; and [4]Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Financial disclosure: See Acknowledgments on page 961.

Correspondence and reprint requests: Junya Kanda, MD, Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan (email: jkanda16@kuhp.kyoto-u.ac.jp).

Received February 27, 2009; accepted April 13, 2009

© 2009 American Society for Blood and Marrow Transplantation

1083-8791/09/158-0001$36.00/0
doi:10.1016/j.bbmt.2009.04.008

downregulating the expression of the cellular iron exporter, ferroportin [14,15]. Hepatic expression of hepcidin can be upregulated by iron loading [16,17] as well as by inflammatory stimuli such as interleukin-6 (IL-6) [18]. Therefore, we hypothesized that serum hepcidin level could be a useful predictor of iron overload and inflammatory condition prior to HSCT. Here, we performed a single-center retrospective study at our institution to evaluate the significance of serum hepcidin levels as a predictor of early treatment-related complications after allogeneic HSCT with special reference to infectious complications.

PATIENTS AND METHODS

Study Population

The study population comprised 66 consecutive adult patients who underwent allogeneic HSCT for the treatment of hematologic malignancies at Kyoto University Hospital from July 2006 to September 2008. A total of 55 patients, excluding those who had received prior transplantations within 1 year or who had any active infections before the current transplantation, were included in the analysis. This study was approved by the Ethics Committee of Kyoto University Graduate School and the Faculty of Medicine. Written informed consent was obtained from all patients.

Serum Analysis

Before the administration of conditioning regimens, serum samples were obtained at around 8:00 am, allocated in tubes, and stored at −80°C until analysis. The levels of serum hepcidin-25 (the main form of active hepcidin peptide) were quantified using a liquid chromatography-tandem mass spectrometry-based assay system following the method described by Murao et al. [19]. Other serum parameters were measured using standard laboratory techniques.

Prophylaxis, Monitoring, and Diagnosis of Infection

The patients were isolated in a single room equipped with a high-efficiency particulate air filter (HEPA) system from 1 day before transplantation until at least 4 weeks after transplantation. No bacterial prophylaxis was prescribed for the patients according to our institutional protocols [20]. Trimethoprim-sulfamethoxazole (160 mg/day [trimethoprim], 3 times a week) was administered as prophylactic therapy for *Pneumocystis jirovecii* pneumonia from the day of admission until the day of transplantation and restarted after the day of neutrophil engraftment. All patients received fluconazole (200 or 400 mg/day) and acyclovir (1000 mg/day) prophylaxis from the period of conditioning until 30 days after transplantation. After the first 30 days, the patients received fluconazole at a dose of 100 mg/day until at least 100 days after transplantation. The administration of acyclovir (400 mg/day) was continued when patients received steroid therapy for acute graft-versus-host disease (aGVHD). For each febrile episode, 1 or 2 sets of blood samples were cultured, and the cultures of specimens other than blood and imaging examinations were performed according to clinical judgment. The occurrence of cytomegalovirus (CMV) infection was closely monitored by CMV pp65 antigenemia testing with C10/C11 monoclonal antibodies (mAbs) from the day after neutrophil engraftment until at least 100 days after transplantation. Documented bacterial infection included any incidence of bloodstream infection or any other bacterial infection. Bloodstream infection was diagnosed if at least 1 of the following criteria was met: (1) blood culture obtained during a febrile episode was positive, at least once, for bacterial organisms not considered to be common skin contaminants; (2) blood culture obtained during a febrile episode was positive for the same common skin contaminant on separate occasions within 72 hours; (3) blood culture was positive, at least once, for a common skin contaminant, and the patient was diagnosed with septicemia, including hypotension (systolic blood pressure, <90 mmHg) and abnormal coagulopathy. Infections other than bloodstream infection were diagnosed if the following criteria were met: (1) bacterial organisms were observed from specimens such as sputum, urine, and stool at least on 2 occasions, and (2) the patient showed symptoms of infection corresponding to those specimens. *Clositridium difficile* enterocolitis was excluded from the analysis, because this disease is toxin-mediated, and cannot be prevented by administration of common bacterial prophylactic agents such as fluoroquinolones, even if patients with a high risk of bacterial infection can be identified by using a putative biomarker. CMV infection was defined as positive if either C10 or C11 antigenemia assay showed at least 2 positive cells per 150,000 leukocytes. Invasive fungal infection was diagnosed according to the criteria of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group [21].

Statistical Analysis

Endpoints included cumulative incidences of documented bacterial infection, fungal infection, CMV infection, and infection-related mortality, and OS within 100 days post transplantation. Patient and transplant characteristics between 2 groups were compared using the Mann-Whitney *U*-test or χ^2 analysis, as appropriate. The day of neutrophil

engraftment was defined as the first of 3 consecutive days when the absolute neutrophil count (ANC) exceeded 500/μL. The day of neutrophil engraftment between 2 groups was compared by using the Mann-Whitney *U*-test. To eliminate the effect of competing risk, the cumulative incidences were assessed using methods described elsewhere [22]. The competing event in the cumulative incidence analyses was defined as death without an event of interest within 100 days post transplantation. OS was estimated using Kaplan-Meier methods. Infection-related death was defined as death associated with any infection within 100 days after transplantation. Standard risk disease was defined as complete remission (CR) in cases of acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), adult T cell leukemia/lymphoma (ATL), Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and untreated or CR in MDS and myeloproliferative disorder (MPD). High-risk disease was defined as statuses other than CR in AML, ALL, ATL, HL, and NHL and in MDS and MPD after treatment. The Cox proportional-hazard model was applied to assess the effect of factors that potentially affected the study endpoints. The following items were added as confounders: recipient's sex (male or female), recipient's age (<50 or ≥50 years), diagnosis (myelogenous or lymphogenous malignancies), risk of disease (standard or high risk), conditioning regimen (reduced or myeloablative intensity [RIC, MA]), type of donor (related or unrelated donor), reticulocyte count ($<60 \times 10^9$ or $\geq 60 \times 10^9$/L), ferritin level (<1000 or ≥1000 mg/dL), and C-reactive protein (CRP) level (<0.3 or ≥0.3 μg/dL). The cutoff points for reticulocyte count and the ferritin and CRP levels were chosen such that we could make optimal use of the information with a proviso that the smaller group contained at least 30% of patients. *P* values of < .05 were considered statistically significant. All analyses were conducted using STATA software version 10 (STATA Corp., College Station, TX).

Table 1. Characteristics of Patients and Transplants

Variables	Hepcidin, Low (<50 ng/mL) n = 38	Hepcidin, High (≥50 ng/mL) n = 17	P Value
Age at transplant			
Median age (range)	47.5 (23–64)	47 (20–63)	.750
Sex			.171
Male	21 (55%)	6 (35%)	
Female	17 (45%)	11 (65%)	
Disease			.612
Myeloid malignancies	23 (61%)	9 (53%)	
AML	15	8	
MDS/MPD	8	1	
Lymphoid malignancies	15 (39%)	8 (47%)	
ALL	4	4	
ATL	4	1	
HL	1	0	
NHL	6	3	
Risk of disease			.051
Standard	22 (58%)	5 (29%)	
High	16 (42%)	12 (71%)	
Conditioning regimen			.545
Myeloablative intensity	19 (50%)	10 (59%)	
Reduced intensity	19 (50%)	7 (41%)	
Prophylaxis against GVHD			.663
Cyclosporine-based	5 (13%)	3 (18%)	
Tacrolimus-based	33 (87%)	14 (82%)	
Type of donor			.181
Related donor			
HLA*-matched	10 (26%)	3 (18%)	
HLA-mismatched	3 (8%)	1 (6%)	
Unrelated donor			
HLA-matched	18 (47%)	5 (29%)	
HLA-mismatched	7 (18%)	8 (47%)	
Source of stem cells			.259
Bone marrow	29 (76%)	10 (59%)	
Peripheral blood	1 (3%)	0 (0%)	
Cord blood	8 (21%)	7 (41%)	
Serum ferritin (μg/dL)			
mean (±SD)	664 (±796)	1551 (±993)	<.001
CRP (mg/dL)			
mean (±SD)	0.36 (±0.68)	0.70 (±1.63)	.176
Reticulocyte ($\times 10^9$/L)			
mean (±SD)	63.7 (±40.2)	64.0 (±42.2)	.979

AML indicates acute myelogenous leukemia; MDS/MPD, myelodysplastic syndrome and myeloproliferative disorders; ALL, acute lymphoblastic leukemia; ATL, acute T cell leukemia/lymphoma; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; GVHD, graft-versus-host disease; Cyclosporine-based, cyclosporine with or without other agents; Tacrolimus-based, tacrolimus with or without other agents; HLA, human leukocyte antigen; CRP, C-reactive protein.
Data are counts of individuals unless specified otherwise.
*HLA compatibility was defined according to the results of serologic or low-resolution molecular typing for HLA-A, -B, and -DR antigens.

RESULTS

Characteristics of Patients and Transplants

Characteristics of patients and transplants are shown in Table 1. The median age of patients was 47 years (range: 20–64 years). The primary disease in these patients was as follows: AML in 23, MDS/MPD in 9, ALL in 8, NHL in 9, HL in 1, and ATL in 5. The risk of diseases was standard in 27 and high in 28 patients. Nearly half of the patients (n = 26) received a RIC regimen. The stem cell sources used were bone marrow (BM) in 39, peripheral blood (PB) in 1, and cord blood (CB) in 15 patients. The median pretransplant serum hepcidin level was 21.6 ng/mL (range: 1.4–371 ng/mL), which was comparable to that of healthy volunteers (median: 19.1 ng/mL [range: 2.3–37 ng/mL]; n = 17) [23]. Because the lower hepcidin level of the third tertile among the patients in this study was 49.1 ng/mL, we set a cutoff hepcidin level of 50 ng/mL for practical use to divide the patients into low- and high-hepcidin groups (n = 17 and 38, respectively). There was no difference in patient and transplant characteristics between the low- and high-hepcidin groups, except for serum ferritin levels (*P* < .001).

Documented Bacterial Infections

There was no significant difference between the days of neutrophil engraftment of the low- and high-hepcidin groups (median day: 21 [range: 14–99] and median day: 22.5 [range: 12–53], respectively, $P = .54$). A total of 16 episodes of bacterial infections were documented; these included 15 episodes of bloodstream infections and 1 episode of pneumonia. No patient experienced more than 1 episode of bacterial infection within 100 days after transplantation. The documented bacterial organisms are listed in Table 2. The main organisms were Gram-negative bacilli in both the low- and high-hepcidin groups. In the antimicrobial-susceptibility tests, 12 of the 13 Gram-negative isolates were sensitive to fluoroquinolone. We documented 2 bacterial infections in the late period of transplantation; 1 patient showed infection at day 89 after transplantation, which was attributed to delayed neutrophil engraftment, and another patient showed infection at day 68, when the neutrophil counts had temporarily decreased. The cumulative incidences of the documented bacterial infection in the low- and high-hepcidin groups were 11% (95% confidence interval [CI], 3%–23%) and 65% (95% CI, 38%–82%), respectively (Figure 1A). In the low-hepcidin group, the cumulative incidence of bacterial infection was lower in patients with a hepcidin level of <25 ng/mL than in those with a hepcidin level ranging from ≥25 to <50 ng/mL (10% [95% CI, 2%–23%] versus 17%, [95% CI, 1%–52%]). Univariate analysis of various potential confounders showed that high hepcidin level was the only factor that affected the cumulative incidence of documented bacterial infection (hazard ratio [HR], 8.98; 95% CI, 2.82–28.57; $P < .001$) (Table 3). To exclude the effect of other confounders, the significance of high hepcidin level was assessed in the stratified category of each confounder (eg, in either the high- or low-ferritin group); we noted consistently high HRs in the high-hepcidin group in each stratified category (data not shown). We also found that hepcidin had a significant impact on the patients, excluding the patients in other specific categories, such as those who received a CB transplant or those who underwent a transplant from an unrelated HLA-mismatched donor (data not shown). Furthermore, the significant effect of hepcidin persisted even after the adjustment for confounders in multivariate analysis (HR, 28.46; 95% CI, 2.51–323.34; $P = .007$) (Table 3). Even when the variables were treated as continuous instead of categoric, the significant effect of hepcidin persisted (HR, 1.01; 95% CI, 1.00-1.01; $P = .001$).

Table 2. Documented Bacterial Organisms within 100 Days after Stem Cell Transplantations

Category	Hepcidin, Low (<50 ng/mL) n = 38	Hepcidin, High (≥50 ng/mL) n = 17
Gram-positive cocci (n)	*Staphylococcus epidermidis* (1)	*Enterococcus faecium* (2)
Gram-negative bacilli (n)	*Klebsiella pneumoniae* (2)	*Klebsiella pneumoniae* (3)
	Enterobacter cloacae (1)	*Escherichia coli* (3)
	Prevotella intermedia (1)	*Pseudomonas aeruginosa* (2)
		Klebsiella oxytoca (1)

P. intermedia was detected in the sputum of 1 patient with pneumonia. Other organisms were detected in blood culture bottles.



Figure 1. The cumulative incidences of documented bacterial infection (A) and cytomegalovirus (CMV) infection (B) at 100 days after stem cell transplantation. Solid black line, the low-hepcidin group (<50 ng/mL); solid gray line, the high-hepcidin group (≥50 ng/mL); CI, confidence interval. CMV infection was not assessable in 2 patients because of early death before neutrophil engraftment.

Other Transplant-Related Complications and Mortality

The cumulative incidences of CMV infection in the low- and high-hepcidin group were 49% (95% CI, 32%–64%) and 45% (95% CI, 20%–67%), respectively (Figure 1B); univariate and multivariate analyses showed no significant difference between the 2 groups (Table 3). All CMV infections were well treated by the administration of ganciclovir or foscarnet. No fungal infection was documented. Therefore, all infection-related deaths were attributed to bacterial infection. The cumulative incidence of infection-related mortality in the low-hepcidin group was 3% (95% CI, 0.2%–12%), whereas that in the high-hepcidin group was 6% (95% CI, 0.4%–24%),

Table 3. Univariate and Multivariate Analyses of Documented Bacterial Infection, CMV Infection, and Overall Survival at 100 Days after Stem Cell Transplantations

	Number	Univariate Analysis		Multivariate Analysis	
		HR (95% CI)	P Value	HR (95% CI)	P Value
1) Documented bacterial infection					
Hepcidin, low (<50 ng/mL)	5/38	1	–	1	–
Hepcidin, high (≥50 ng/mL)	11/17	8.98 (2.82–28.57)	<.001	28.46 (2.51–323.34)	.007
2) CMV antigenemia (C10 or C11 ≥2)					
Hepcidin, low (<50 ng/mL)	18/37	1	–	1	–
Hepcidin, high (≥50 ng/mL)	7/16	0.97 (0.40–2.32)	.939	0.63 (0.16–2.49)	.511
3) Overall survival					
Hepcidin, low (<50 ng/mL)	36/38	1	–	–	–
Hepcidin, high (≥50 ng/mL)	14/17	3.60 (0.60–21.56)	.161	–	–

CMV indicates cytomegalovirus; CI, confidence interval.
Hazard ratios (HRs) in multivariate analysis were adjusted for recipient's sex (male or female), recipient's age (<50 or ≥50 years), diagnosis (myelogenous or lymphoid malignancies), risk of disease (standard or high risk), conditioning regimen (reduced or myeloablative intensity), type of donor (related or unrelated donor), reticulocyte count (<60 × 109 or ≥60 × 10^9/L), ferritin level (<1000 or ≥1000 mg/dL), and C-reactive protein (CRP) level (<0.3 or ≥0.3 μg/dL). Overall survival was not analyzed in the multivariate model because of the low incidence of death.

with no statistical difference between the 2 groups. OS at 100 days after transplantation in the low- and high-hepcidin groups was 95% (95% CI, 81%–99%) and 82% (95% CI, 55%–94%), respectively (Figure 2). No significant difference in OS was observed (Table 3).

DISCUSSION

In our cohort of patients who underwent allogeneic HSCT for hematologic malignancies, we found a significant association between the pretransplant serum hepcidin levels and the cumulative incidence of documented bacterial infection. To our knowledge, this is the first study that has evaluated the clinical significance of serum hepcidin levels in predicting transplant-related complications; the findings suggest that the pretransplant serum hepcidin level can be used as a good pretransplant biomarker to predict bacterial infection in a patient scheduled for HSCT.



Figure 2. Kaplan-Meier estimate of OS at 100 days after stem cell transplantation. Solid black line, the low-hepcidin group (<50 ng/mL); solid gray line, the high-hepcidin group (≥50 ng/mL); CI, confidence interval.

Hepcidin production is regulated by at least 3 factors: iron load [16,17], inflammation [18], and unknown erythropoietic signals [23-25]. Therefore, the good predictive value of hepcidin with respect to the incidence of documented bacterial infection can be partly explained by the cumulative effect of at least these 3 factors on bacterial infection. Iron overload increases the level of circulating non-transferrin-bound iron, which is known to amplify free-radical reactions in inflammatory or ischemia-related conditions [7,26]. Such reactions could enhance tissue damage such as mucositis during the conditioning regimen, thereby allowing bacterial translocation through the damaged mucosa [27]. In addition, iron is a necessary nutrient for bacteria and fungus [28]. The association between hemochromatosis, 1 of the iron overload disorders, and infection with certain organisms has already been described [29]. Therefore, the high hepcidin levels might reflect iron overload status, which has an adverse effect on bacterial infections. Second, a high hepcidin level may indicate inflammation because of a latent bacterial infection that was undetectable before HSCT, but may surface in posttransplant neutropenic status. Last, a high hepcidin level could reflect suppressed erythropoiesis, probably because of the short duration from the last chemotherapy to the start of the conditioning regimen for transplantation. Repeated cytotoxic chemotherapy in a short period may exacerbate tissue damage and increase the risk of bacterial infection.

Although serum ferritin levels do not necessarily correlate with the amount of iron load in patients with inflammation or specific diseases [1,30,31], it is frequently used and regarded as a indicator of iron overloading, and several studies have demonstrated the association between high ferritin levels and treatment-related mortality (TRM) [3,11]. In this cohort, an elevation of serum ferritin level was not found to be a significant risk factor for bacterial infection,

whereas an elevated hepcidin level was a strong risk factor even after adjustment for other potential confounders. Furthermore, we observed consistent association of high hepcidin levels with high risk for developing bacterial infection when analyses were confined to either the low- or high-ferritin subgroups. These findings collectively suggest that hepcidin can be used as a better predictor of documented bacterial infections than serum ferritin levels. Moreover, various new techniques to quantify hepcidin-25, such as a competitive enzyme-linked immunoassay as well as mass spectrometry-based methods, have been recently developed [19,25,32,33]. Standardization of those methods will make it possible to use the serum hepcidin level as a biomarker in routine clinical practice.

Hepcidin was first isolated and characterized as an antimicrobial peptide in human blood [12]. In radial diffusion assays, synthetic hepcidin suppressed the growth of several strains of Gram-positive bacteria and some strains of Gram-negative bacteria, but not of *Escherichia coli* or *Pseudomonas fluorescens*. Our findings pertaining to the adverse association of high hepcidin levels with bacterial infection indicated that the bactericidal effect of hepcidin was either considerably limited in neutropenic settings such as HSCT or was ineffective on the bacterial organisms observed in our cohort. Moreover, we observed a significant adverse effect of hepcidin even after the adjustment for potential confounders, suggesting that hepcidin itself may play an unknown biologic role in susceptibility to bacterial infection, or it may represent an unknown surrogate marker for predicting bacterial infection. To answer this issue, the significance of pretransplant serum hepcidin levels needs to be evaluated in a more homogeneous group of patients having the same level of confounders.

We did not detect any adverse effect of high hepcidin levels on infection-related mortality or OS at 100 days after transplantation, although there was a marked difference in the incidence of bacterial infection. One possible explanation for this observation is that bacterial infection of the blood was well managed by prompt and appropriate treatment with antibiotics in our transplant centers. However, because the incidence of early death after HSCT is considerably low, the effect of bacterial infection on early mortality should be evaluated in larger cohort studies to gain enough statistical power for comparison. Alternatively, selective prophylactic administration of oral antibiotics such as fluoroquinolones to patients with a high risk of bacterial infection may be an effective approach; however, this approach will be effective only if most of the bacterial isolates at the transplant center are sufficiently sensitive to these prophylactic antibiotics. With regard to other endpoints, there was no association between high hepcidin levels and the incidence of CMV infection. The effect of hepcidin level on the incidence of fungal infection could not be evaluated because of the very low incidences of these conditions in our cohorts. These effects should also be evaluated in studies with a larger cohort in the future.

The present study, however, has some limitations. We cannot exclude the possibility of a pseudonegative result for bloodstream infection, because broad-spectrum antibiotics were administered to all neutropenic patients at the time of blood culture, regardless of the results of blood culture. In addition, the retrospective study design and heterogeneous background of diseases and transplantation procedures could also bias the results. Particularly, in the small cohort of 55 patients, the adjustment of HRs by confounders may be incomplete. In particular, the higher proportion of CB transplants and the high risk of diseases in the high-hepcidin group may cause bias, although we found consistently high HRs in the high-hepcidin group in various stratified categories. Therefore, larger studies are necessary to confirm our results.

In conclusion, our study revealed that the pretransplant serum hepcidin level was significantly associated with bacterial infection, particularly bloodstream infection, suggesting that quantification of serum hepcidin levels could be useful for predicting early bacterial complications. Prophylactic antibiotic therapy based on the local sensitivities of common bacterial isolates can be considered in the patients with high hepcidin levels who are undergoing allogeneic HSCT. Larger prospective studies are, however, warranted to confirm our findings.

ACKNOWLEDGMENTS

Financial disclosure: This work was supported in part by a grant-in-aid for scientific research from the Ministry of Education, Science, Sports, and Culture of Japan; a grant from the Takeda Science Foundation; and a grant for Project Research from the High-Technology Center of Kanazawa Medical University (H2007-2). The authors are grateful to Rie Goi and Mika Kobayashi, for their expert data management and secretarial assistance, and all the transplant teams for their dedicated care of the patients and donors.

Conflict of interest: N.T. declares that he is the President of Medical Care Proteomics Biotechnology Co. Ltd. (Ishikawa-ken, Japan), a startup company, the stock of which is not publicly traded. The other authors declare that they have no conflicts of interest relevant to this paper.

REFERENCES

1. Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. *Bone Marrow Transplant*. 2008;41: 997-1003.

2. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. *Blood*. 2007;109: 4586-4588.
3. Altes A, Remacha AF, Sarda P, et al. Early clinical impact of iron overload in stem cell transplantation. A prospective study. *Ann Hematol*. 2007;86:443-447.
4. Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. *Bone Marrow Transplant*. 2006;37:857-864.
5. Morado M, Ojeda E, Garcia-Bustos J, et al. BMT: serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study. *Hematology*. 2000;4:505-512.
6. Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2008;42:799-805.
7. Evens AM, Mehta J, Gordon LI. Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. *Bone Marrow Transplant*. 2004;34:561-571.
8. Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. *Cancer*. 2007;110:1303-1306.
9. Platzbecker U, Bornhauser M, Germing U, et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). *Biol Blood Marrow Transplant*. 2008; 14:1217-1225.
10. Altes A, Remacha AF, Sureda A, et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2002;29:987-989.
11. Kataoka K, Nannya Y, Hangaishi A, et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2009;15: 195-204.
12. Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. *FEBS Lett*. 2000;480:147-150.
13. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. *J Biol Chem*. 2001; 276:7806-7810.
14. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science*. 2004;306:2090-2093.
15. Ganz T. Hepcidin—a regulator of intestinal iron absorption and iron recycling by macrophages. *Best Pract Res Clin Haematol*. 2005;18:171-182.
16. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. *J Clin Invest*. 2004;113:1271-1276.
17. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. *J Biol Chem*. 2001;276:7811-7819.
18. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. *Blood*. 2003;101:2461-2463.
19. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. *Rapid Commun Mass Spectrom*. 2007;21:4033-4038.
20. Saito T, Yoshioka S, Iinuma Y, et al. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit. *Eur J Clin Microbiol Infect Dis*. 2008;27:209-216.
21. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clin Infect Dis*. 2002;34:7-14.
22. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med*. 1999;18: 695-706.
23. Kanda J, Mizumoto C, Kawabata H, et al. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. *Haematologica*. 2008;93:1550-1554.
24. Weizer-Stern O, Adamsky K, Amariglio N, et al. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. *Am J Hematol*. 2006;81: 479-483.
25. Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. *Clin Chem*. 2007;53: 620-628.
26. McCord JM. Iron, free radicals, and oxidative injury. *Semin Hematol*. 1998;35:5-12.
27. Sahlstedt L, Ebeling F, von Bonsdorff L, Parkkinen J, Ruutu T. Non-transferrin-bound iron during allogeneic stem cell transplantation. *Br J Haematol*. 2001;113:836-838.
28. Weinberg ED. Iron availability and infection. *Biochim Biophys Acta*. 2008. [Epub ahead of print].
29. Khan FA, Fisher MA, Khakoo RA. Association of hemochromatosis with infectious diseases: expanding spectrum. *Int J Infect Dis*. 2007;11:482-487.
30. Lee MH, Means RT Jr. Extremely elevated serum ferritin levels in a university hospital: associated diseases and clinical significance. *Am J Med*. 1995;98:566-571.
31. Olive A, Junca J. Elevated serum ferritin levels: associated diseases and clinical significance. *Am J Med*. 1996;101:120: author reply 122.
32. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. *Blood*. 2008;112:4292-4297.
33. Murphy AT, Witcher DR, Luan P, Wroblewski VJ. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. *Blood*. 2007;110: 1048-1054.

Int J Hematol (2009) 89:538–545
DOI 10.1007/s12185-009-0306-5

ORIGINAL ARTICLE

Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning

Chisaki Mizumoto · Junya Kanda · Tatsuo Ichinohe · Takayuki Ishikawa · Masashi Matsui · Norimitsu Kadowaki · Tadakazu Kondo · Kazunori Imada · Masakatsu Hishizawa · Hiroshi Kawabata · Momoko Nishikori · Kouhei Yamashita · Akifumi Takaori-Kondo · Toshiyuki Hori · Takashi Uchiyama

Received: 24 January 2009 / Revised: 10 March 2009 / Accepted: 17 March 2009 / Published online: 11 April 2009
© The Japanese Society of Hematology 2009

Abstract We evaluated the efficacy of a post-grafting immunosuppressive regimen consisting of tacrolimus, methotrexate, and mycophenolate mofetil (MMF) in 21 adults (median age, 55 years) with poor-risk hematologic malignancy who underwent unrelated bone marrow transplantation after fludarabine-based reduced-intensity conditioning (RIC). In combination with intravenous tacrolimus and minidose methotrexate (5 mg/m^2 on days 1, 3, and 6), MMF was orally administered at 30 mg/kg daily in three divided doses between days 7 and 27. All patients achieved neutrophil recovery with donor-type chimerism at a median of 19 days (range, 13–35). Cumulative incidences of grades II–IV and III–IV acute graft-versus-host disease (GVHD) were 33% (95% CI, 15–53%) and 5% (95% CI, 0.3–20%), respectively. Five of 20 evaluable patients developed extensive chronic GVHD. Toxicities associated with the use of MMF were acceptable, although one patient experienced intractable GVHD immediately after the cessation of MMF. With a median follow-up of 24 months, overall survival at 3 years was 38% (95% CI, 14–63%). No late graft failure was observed. In conclusion, post-transplant MMF combined with tacrolimus and methotrexate was well tolerated and conferred stable donor cell engraftment, low risk of severe acute GVHD, and encouraging overall survival in unrelated donor marrow transplantation after RIC regimens.

Keywords Mycophenolate mofetil · Reduced-intensity conditioning · Unrelated donor · Bone marrow transplantation · Graft-versus-host disease

C. Mizumoto · J. Kanda · T. Ichinohe (✉) · T. Ishikawa · M. Matsui · N. Kadowaki · T. Kondo · M. Hishizawa · H. Kawabata · M. Nishikori · K. Yamashita · A. Takaori-Kondo · T. Hori · T. Uchiyama
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan
e-mail: nohe@kuhp.kyoto-u.ac.jp

K. Imada
Department of Hematology, Kokura Memorial Hospital, Kita-kyushu, Japan

1 Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) with reduced-intensity conditioning (RIC) regimens is increasingly employed as a treatment option for various hematologic disorders. RIC transplantations using cytokine-mobilized peripheral blood stem cells (PBSC) have been reported to yield comparable outcomes with conventional myeloablative HSCT at least in selected patients [1–4]. However, previous reports have consistently shown that RIC transplantations using bone marrow (BM) graft, especially from an unrelated donor, are associated with an increased risk of graft failure and treatment-related toxicity as compared with those using PBSC, although confirmatory data from randomized-controlled trials are currently unavailable [5–8]. To improve outcomes after unrelated BM transplantation conditioned with non-myeloablative or reduced-intensity regimens, it would be beneficial to introduce a newer post-transplant immunosuppressive protocol which can effectively prevent both graft rejection and severe graft-versus-host disease (GVHD).

Mycophenolate mofetil (MMF) is an esterified prodrug of mycophenolic acid (MPA), which has pleiotropic immunosuppressive actions [9, 10]. MPA preferentially inhibits de novo purine nucleotide synthesis in T-cells and B-cells via inhibition of inosine-5′-monophosphate

dehydrogenase, interfering with their proliferation. MPA also suppresses dendritic cell maturation and can induce T-cell apoptosis. The use of MMF in combination with cyclosporine or tacrolimus was proven to be active in promoting hematopoietic stem cell engraftment after non-myeloablative HSCT using fludarabine and low-dose total-body irradiation (TBI) conditioning [11, 12], and was also shown to be as effective as the standard post-grafting immunosuppression with cyclosporine and methotrexate (MTX) in preventing severe acute GVHD after myeloablative HSCT from an HLA-matched related donor [13, 14].

A combination of tacrolimus and minidose MTX has been widely used as GVHD prophylaxis in RIC transplantation as well as in conventional HSCT from adult unrelated donors [15, 16]. Because MMF and tacrolimus are shown to have synergistic immunosuppressive actions in experimental and clinical organ transplantations [17, 18], we hypothesized that MMF in conjunction with tacrolimus and minidose MTX would be more efficacious than a combination of tacrolimus/MTX alone. In this single-center study, we retrospectively evaluated the efficacy of such triple combination as an alternative peritransplant immunosuppressive protocol in unrelated donor RIC transplantation using exclusively BM as a stem cell source.

2 Patients and methods

2.1 Patients

Among 61 consecutive adult patients who received BM transplantation from an unrelated donor between 2003 and 2006 at Kyoto University Hospital, those who fulfilled the following criteria were selected for the study: having a hematologic malignant disease; having an unrelated donor who was serologically matched at HLA-A, -B, and -DR antigens, allowing a single-allele mismatch identified by high-resolution DNA typing; receiving fludarabine-based RIC because of having a history of chemoradiotherapy precluding the use of myeloablative conditioning or having 55 through 69 years of age; receiving GVHD prophylaxis consisted of intravenous tacrolimus, minidose MTX and oral MMF. All patients had an adequate cardiac, pulmonary, hepatic, and renal function at the time of transplantation and did not have therapy-resistant central nervous system involvement or active infectious disease. A total of 21 patients fulfilled these criteria and considered evaluable for the study. With respect to disease status at transplant, patients who received transplant without prior cytotoxic chemotherapy or in first complete remission were considered to have an early disease, while those who underwent transplantation in all the other conditions were considered to have an advanced disease. All the patients with early disease were considered to have resistance to conventional chemotherapy or to have a high risk of relapse: those included two cases with untreated high-risk myelodysplastic syndrome, one with chronic active Epstein-Barr virus infection and one with adult T-cell leukemia/lymphoma in first remission. This study was approved by the Institutional Review Board and Ethic Committee of Kyoto University; written informed consent for transplantation was obtained from all participating patients.

2.2 Study end points

The primary end points of the study were donor cell engraftment and the occurrence of grade II–IV acute GVHD. Secondary end points included the neutrophil and platelet recovery, the occurrence of extensive chronic GVHD, progression or relapse of primary disease, and death from any cause.

Donor cell engraftment was defined as the detection of donor-type chimerism among unfractionated BM-nucleated cells with concomitant neutrophil recovery. Date of neutrophil recovery was defined as the first 3 consecutive days with the absolute neutrophil count (ANC) higher than 0.5×10^9/L. Date of platelet recovery was defined as the first 7 consecutive days with platelet count exceeding 20×10^9/L without transfusion. Acute GVHD was diagnosed and graded according to the conventional criteria [19]. Chronic GVHD was diagnosed and staged as limited or extensive on the basis of traditional criteria among patients who survived more than 90 days after transplantation [20]. Disease response and progression were defined by the standard criteria [21–25]. Toxicity observed between days 0 and 100 after transplantation was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events ver 3.0. Non-infectious pulmonary complications were diagnosed on the basis of clinical manifestations, radiologic findings, and the results of pulmonary function tests if available [26].

2.3 HLA typing and chimerism analysis

Compatibility at *HLA-A*, *-B*, and *-DRB1* loci between patients and donors was determined by standard serologic technique and high-resolution DNA typing as described elsewhere [27]. *HLA-C* compatibility was not included as a criterion for donor selection because routine *HLA-C* allele typing for the screening of unrelated donors was not available before April 2004. Donor cell chimerism levels among unfractionated BM-nucleated cells were evaluated on day 28 and thereafter at the appropriate time point by polymerase chain reaction-based analysis of polymorphic microsatellite regions for recipients of sex-matched graft or fluorescent in situ hybridization analysis of sex chromosomes for sex-mismatched pairs as described previously [28].

2.4 Transplantation procedure

Preparative regimens were assigned according to diagnosis and disease status at transplantation. Fourteen patients received fludarabine 25 mg/m^2/day for 5 consecutive days (days −6 to −2) in combination with oral busulfan 1 mg/kg every 6 h for 2 days (days −3 and −2) followed by 400 cGy of TBI in 2 fractions (on day −1 and/or day 0). One patient who had a history of TBI-based myeloablative allogeneic transplantation received the same dose schedule of fludarabine plus busulfan regimen without 400 cGy TBI. Four patients received fludarabine at the same daily dose from days −8 through −4 combined with melphalan 70 mg/m^2/day on days −3 and −2. The remaining two patients without a history of cytotoxic chemotherapy received 200 cGy TBI in a single fraction in addition to the fludarabine plus melphalan regimen.

All BM collections from unrelated donors were facilitated through the Japan Marrow Donor Program [27]. On day 0, BM graft was infused without T-cell depletion; ABO major-mismatched or bidirectionally mismatched graft was processed to isolate mononuclear cell suspension using COBE Spectra (Gambro BCT, Lakewood, CO, USA) or CS-3000 Plus (Baxter Corp., Deerfield, IL, USA) according to the manufacture's instruction, while ABO minor-mismatched graft was plasma depleted before infusion. Eleven patients who were suspected to develop bacterial infection during the first week after transplantation or who were considered to be at high risk for infectious complications because of prior history of allogeneic transplantation received infusional or subcutaneous granulocyte colony-stimulating factor 5 μg/kg/day from day 7 until ANC exceeded 0.5×10^9/L.

Continuous intravenous administration of tacrolimus in a dose of 0.02 mg/kg/day was started on day −3 in patients receiving busulfan-based conditioning or on day −1 in patients receiving melphalan-based conditioning with therapeutic monitoring which targeted blood levels of 10–15 ng/ml at least until day 28 after transplantation, converted to twice-daily oral administration at an appropriate time to maintain trough levels between 5 and 10 ng/ml until day 100, followed by stepwise tapering over 3–6 months if active GVHD was absent. MTX at a dose of 5 mg/m^2 was intravenously injected on days 1, 3, and 6; MMF 30 mg/kg/day was orally administered in three divided doses from days 7 to 27. After day 28, MMF was discontinued without tapering if acute GVHD was absent or gradually tapered if ongoing acute GVHD was present. Patients who developed grade II–IV acute GVHD were initially treated with methylprednisolone or prednisolone at a dose of 1–2 mg/kg/day. All patients received supportive care including blood product transfusion and prophylaxis against opportunistic infections according to our institutional protocols [29].

2.5 Statistical analysis

Probabilities of neutrophil recovery, platelet recovery, and grade II–IV or grade III–IV acute GVHD were calculated by cumulative incidence estimates, treating death without the respective event as a competing risk [30]. Overall survival from the date of transplantation until the date of death from any cause was estimated by the Kaplan–Meier method; progression-free survival was estimated from the date of transplantation until the date of disease progression, relapse, or death from any cause. Data on patients who were alive at the time of last follow-up were censored. All statistical analyses were performed using STATA version 10 software (Stata Corp., College Station, TX, USA) based on dataset available on 10 January 2008.

3 Results

3.1 Patient and transplant characteristics

Table 1 shows the characteristics of the patients and transplantation procedures. A total of 17 patients (86%) had an advanced disease at transplantation, while the remaining 4 patients had an early disease. With respect to the compatibility at *HLA-A*, *-B*, and *-DRB1*, five patients (24%) received a single-allele mismatched graft, three had a mismatch at *HLA-A* and two at *HLA-DRB1*. Two of these five patients were found to have an additional allele mismatch at *HLA-C*. The median total number of nucleated cells included in the collected BM graft was 3.0 (range, 1.2–4.0) $\times 10^8$ per kg of the recipient's body weight.

3.2 Engraftment

All patients achieved successful donor cell engraftment. The cumulative incidence of neutrophil recovery $>0.5 \times 10^9$/L by day 35 was 100%, with a median time of 19 days (range, 13–35 days) (Fig. 1a). The cumulative probability of platelet recovery $>20 \times 10^9$/L by day 42 was 81%, with a median time of 26 days (range, 13–91 days) (Fig. 1b). Two patients had experienced relapse on days 39 and 67 after transplantation without platelet recovery. No secondary graft failure was observed.

3.3 Acute and chronic GVHD

Acute GVHD was evaluable in all the patients. A total of seven patients developed grade II–IV acute GVHD: grade II in 6 and grade IV in 1. Cumulative incidence of developing grade II–IV acute GVHD at day 100 after transplantation was 33% (95% CI, 15–53%), and that of grade III–IV acute GVHD was 5% (95% CI, 0.3–20%)

Table 1 Patient and transplant characteristics

	$n = 21$
Median recipient age (range) (years)	52 (24–66)
Recipient sex, *n*	
Female/male	12/9
Diagnosis, *n*	
Acute myeloid leukemia	5
Myelodysplastic syndrome	4
Adult T-cell leukemia/lymphoma	4
Follicular lymphoma	3
Hodgkin lymphoma	1
Plasma cell myeloma	2
Chronic active EBV infection	1
Extranodal NK/T-cell lymphoma	1
Disease status at transplantation, *n*	
Early disease	
CR1	1
Untreated	3
Advanced disease	
CR > 1	4
PR	8
Progressive disease	5
Median donor age (range) (years)	34 (20–48)
HLA matching (at HLA-A, -B, -DRB1), *n*	
Match	16
Single-allele mismatch	5
ABO incompatibility, *n*	
Match	9
Minor	3
Major	5
Bidirectional	4
Conditioning, *n*	
Fludarabine + busulfan + 4 Gy TBI	14
Fludarabine + busulfan	1
Fludarabine + melphalan + 2 Gy TBI	2
Fludarabine + melphalan	4

EBV Epstein-Barr virus, *CR* complete remission, *PR* partial remission, *TBI* total-body irradiation



Fig. 1 Cumulative incidence of neutrophil recovery (**a**) and platelet recovery (**b**)



Fig. 2 Cumulative incidences of grade II–IV (*solid line*) and grade III–IV (*dashed line*) acute GVHD

(Figs. 2, 3). Chronic GVHD was observed in 11 of 20 (55%) evaluable patients who survived 100 days after transplantation: limited type in 6 and extensive type in 5.

3.4 Transplant-related toxicities and infectious complications

Transplant-related organ toxicities during the first 100 days after transplantation are shown in Table 2. Mild to moderate gastrointestinal symptoms considered to be associated with preparative regimens were frequently observed, although other adverse events were mostly moderate. One patient was required to discontinue MMF on day 9 because of grade III diarrhea.

Eighteen patients (86%) experienced 38 episodes of documented or suspected infectious complications (Table 3). Fourteen episodes of culture-negative neutropenic fever were reported. Five episodes of microbiologically documented bacterial infection were observed in four patients:

Springer



Fig. 3 Probabilities of overall survival (*solid line*) and progression-free survival (*dotted line*) after transplantation

Table 2 Transplant-related toxicities

	CTCAE grade I–II	CTCAE grade III
Vomiting	3 (14%)	6 (28%)
Stomatitis	5 (24%)	6 (28%)
Diarrhea	9 (43%)	3 (14%)
Liver dysfunction	5 (24%)	3 (14%)
Renal dysfunction	3 (14%)	0 (0%)
Headache	0 (0%)	2 (10%)
Pleural effusion	2 (10%)	0 (0%)
Myalgia	2 (10%)	0 (0%)

CTCAE common terminology criteria for adverse events

Table 3 Infectious complications

	No. of episodes
Culture-negative febrile neutropenia	14
Bacteremia	4
Clostridium difficile-associated diarrhea	1
Phlegmone	1
Neutropenic enterocolitis	1
CMV antigenemia	11
Cystitis	5
Aseptic meningitis	1
Total	38

CMV cytomegalovirus

bloodstream infection ($n = 4$) and *Clostridium difficile*-associated enteritis ($n = 1$). Two episodes of suspected bacterial infections were reported: phlegmone ($n = 1$) and neutropenic enterocolitis ($n = 1$). Eleven patients became positive for cytomegalovirus (CMV) antigenemia; one of them developed CMV-associated hepatitis and enteritis. Adenovirus was detected from the urine from one of five patients who developed cystitis. One patient experienced aseptic meningitis. No varicella-zoster virus infection was observed. There was no death directly attributable to infectious events until day 100.

Six patients developed non-infectious pulmonary complications between 3 and 14 months after transplantation: bronchiolitis obliterans ($n = 2$), bronchiolitis obliterans-organizing pneumonia ($n = 1$), diffuse alveolar hemorrhage ($n = 1$), and idiopathic interstitial pneumonia ($n = 2$). One patient developed secondary gastric cancer at 34 months after transplantation.

3.5 Survival and treatment-related mortality

Eleven patients were alive and 10 of them were disease-free at a median follow-up of 24 months (range, 3–31 months). Among four patients who had an early disease at transplant, one experienced relapse on day 292. Fifteen of 17 patients who had an advanced disease maintained or attained remission after transplantation, but seven of them eventually relapsed between days 67 and 363. Two of the relapsed patients received donor lymphocyte infusion after chemotherapy, and durable remission lasting more than 16 months was observed in one patient.

Ten patients were deceased between 76 and 1093 days after transplantation. Six patients succumbed to disease progression and four patients died of treatment-related complications including interstitial pneumonia ($n = 1$), bronchiolitis obliterans followed by diffuse alveolar damage ($n = 1$), intracranial hemorrhage during exacerbation of bronchiolitis obliterans ($n = 1$), and secondary gastric cancer ($n = 1$). The probabilities of overall survival and progression-free survival at 3 years after transplantation were 38% (95% CI, 14–63%) and 33% (95% CI, 12–55%), respectively.

4 Discussion

In this study, we evaluated the efficacy of a combination of tacrolimus, minidose MTX, and MMF as post-transplant immunosuppression in RIC transplantations using BM grafts from an HLA-A, -B, -DR antigen compatible unrelated donor. This triple regimen conferred stable donor cell engraftment, low risk of severe acute GVHD, and encouraging overall survival with acceptable toxicity profiles.

Recent introduction of RIC has provided the opportunity to enjoy long-term disease-free survival in patients with hematologic malignancies who were previously ineligible for allogeneic HSCT because of elder age or pre-existing comorbidity. It has been shown that RIC HSCT using alternative stem cell source is a feasible treatment option when an HLA-matched related donor is not available, albeit at the expense of substantial risk of more serious

transplant-related complications. Among the first 285 patients who underwent unrelated RIC HSCT through the National Marrow Donor Program, the respective incidence rates of primary graft failure, grade III–IV acute GVHD, and treatment-related mortality at 3 months after transplantation were 11, 22, and 19%, respectively [7].

It should also be noticed that RIC transplantations using BM as a stem cell source have been reported to be associated with a higher risk of graft failure when compared with those using cytokine-mobilized PBSC, especially in the unrelated donor setting [6, 7]. As compared with BM, PBSC grafts usually contain more than ten times higher number of T-cells and 2–4 times greater number of $CD34^+$ cells, which would have a beneficial impact on successful engraftment after RIC [31]. In a study which compared the engraftment kinetics after transplantation of PBSC and BM with an identical non-myeloablative conditioning, the number of patients who achieved full donor chimerism was significantly lower in the BM group [32]. These observations suggested that, to improve the outcomes after RIC transplantation using BM grafts from unrelated donors, it is important to develop more optimal post-transplant immunosuppressive protocol which can effectively prevent graft rejection as well as severe GVHD.

In preclinical canine models and clinical experiences of HSCT after truly non-myeloablative regimen using low-dose TBI with or without fludarabine as pre-transplant conditioning, post-transplant administration of MMF was shown to improve the rate of successful donor cell engraftment [11, 33]. Therefore, we hypothesized that the addition of MMF to the standard immunosuppression with tacrolimus plus minidose MTX might facilitate engraftment after unrelated BM allografting with RIC. In support of this hypothesis, all the patients in this study achieved durable donor cell engraftment without experiencing serious morbidity associated with delayed hematopoietic recovery or late graft failure. However, this promising result awaits further validation because the probability of engraftment can also be influenced by the type and intensity of RIC regimens or by the use of pre-transplant anti-thymocyte globulins or T-cell-depleting monoclonal antibodies. Onishi et al. reported the outcomes of unrelated BM transplantation after RIC with fludarabine, busulfan, and 4 Gy TBI among a cohort of 17 patients with various hematologic malignant diseases. Although all the patients in their report initially achieved successful engraftment with the use of conventional post-transplant immunosuppression composed of cyclosporine and MTX, 2 of them subsequently developed secondary graft failure [8]. This observation suggests that the intensification of conditioning with 4 Gy TBI does not always confer sustained engraftment, at least in the setting of unrelated marrow transplantation.

In contrast, the role of MMF in ameliorating acute GVHD has been controversial at least when administered solely with calcineurin inhibitors. Recently, Koh et al. [34] reported that the post-grafting MTX combined with cyclosporine and MMF significantly reduced the risk of grade III–IV acute GVHD as compared with a combination of cyclosporine and MMF. Consistent with their experience, the cumulative incidence of severe acute GVHD after our triple combination was 5%, encouragingly lower than those previously reported in the analysis of unrelated BMT through the Japan Marrow Donor Program, while the incidence of extensive chronic GVHD was apparently similar [27, 35]. However, an important concern regarding the intensification of post-transplant immunosuppressive regimen is an increased risk of infection or relapse. In this study, a substantial proportion of patients developed manageable infections and experienced disease progression within 1 year after transplantation. Although the incidence rates of these events might be adversely affected by the high proportion of patients who had an advanced disease at transplantation, further studies are needed to elucidate whether our triple immunosuppressive regimen may increase the risk of infectious complications or may compromise the graft-versus-tumor effect after RIC HSCT [36, 37].

An unresolved issue in the present study is a pharmacokinetic/pharmacodynamic profile of MMF when combined with tacrolimus and MTX. The increased mean total plasma MPA concentrations at steady state were reported to be associated with higher donor cell chimerism after unrelated non-myeloablative transplantation, while the lower MPA levels were shown to be a predictor of graft rejection [38]. We administered MMF in three divided doses rather than in twice-daily doses because the former is more likely to confer higher mean total MPA concentrations [38, 39]. Because it is speculated that the bioavailability of oral MMF is highly variable depending on the degree of gastrointestinal mucosal damage and donor-recipient pharmacogenomic backgrounds [40], it is important in the future studies to evaluate the association of MPA pharmacodynamics with the risk of post-transplant immunologic complications such as graft rejection, acute GVHD, and infections. Furthermore, appropriate dosing of MMF would be affected by the type of combined calcineurin inhibitor: cyclosporine is reported to decrease MPA exposure due to delay of the excretion of the MPA metabolites, while tacrolimus is less likely to cause drug interaction with MPA [41, 42].

In conclusion, our study demonstrated the feasibility and efficacy of using a triple combination of tacrolimus, minidose MTX and MMF as post-grafting immunosuppression after RIC BM transplantation from unrelated donors. Because this triple regimen conferred high

probability of sustained donor engraftment with an acceptable risk of transplant-related complications, further studies are warranted to confirm its efficacy in a larger population including patients who receive HLA-mismatched family donor grafts or unrelated cord blood units with dose-reduced conditioning.

Acknowledgments The authors thank Dr. Martin Körbling (Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center) for his assistance in developing our transplant program and critical reading of the manuscript. We also thank the physicians and nurses at Kyoto University Hospital for their dedicated care for the patients and donors.

References

1. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304–12. doi:10.1038/sj.leu.2403967.
2. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105:1810–4. doi:10.1182/blood-2004-05-1947.
3. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–46. doi:10.1182/blood-2005-11-4503.
4. Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12:1326–34. doi:10.1016/j.bbmt.2006.08.035.
5. Bornhäuser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R, et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res. 2001;7:2254–62.
6. Maris MB, Niederwieser D, Sandmeier BM, Storer B, Stuart M, Maloney D, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021–30. doi:10.1182/blood-2003-02-0482.
7. Giralt S, Logan B, Rizzo D, Zhang MJ, Ballen K, Emmanoulides C, et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant. 2007;13:844–52. doi:10.1016/j.bbmt.2007.03.011.
8. Onishi Y, Mori S, Kusumoto S, Sugimoto K, Akahane D, Morita-Hoshi Y, et al. Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation. Int J Hematol. 2007;85:256–63. doi:10.1532/IJH97.06199.
9. Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant. 2001;27:1255–62. doi:10.1038/sj.bmt.1703076.
10. Allison AC, Eugui EM. Mechanism of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation. 2005;80(Suppl 2):S181–90. doi:10.1097/01.tp.0000186390.10150.66.
11. McSweeney PA, Niederwieser D, Shizuru JA, Sandmeier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–400. doi:10.1182/blood.V97.11.3390.
12. Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB, et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant. 2006;12:217–25. doi:10.1016/j.bbmt.2005.10.012.
13. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowsky E, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;34:621–5. doi:10.1038/sj.bmt.1704647.
14. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005;11:495–505. doi:10.1016/j.bbmt.2005.03.006.
15. Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood. 1996;88:4383–9.
16. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003;102:3052–9. doi:10.1182/blood-2003-03-0855.
17. Tanabe M, Todo S, Murase N, Irish W, Miyazawa H, Fujisaki S, et al. Therapeutic synergism between low-dose FK506 and antimetabolites in rat allogeneic heart transplantation. Transplant Proc. 1995;27:364–5.
18. Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation. 1998;65:180–7. doi:10.1097/00007890-199801270-00006.
19. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.
20. Sullivan KM, Agura E, Anasetti C, Appelbaum FR, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–9.
21. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813–9.
22. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndrome. Blood. 2000;96:3671–4.
23. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an International workshop to standardize response criteria for non-Hodgkin's lymphomas NCI sponsored International Working Group. J Clin Oncol. 1999;17:1244–53.

24. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol. 1998;102:1115–23. doi:10.1046/j.1365-2141.1998.00930.x.
25. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375–82. doi:10.1046/j.1365-2141.2001.02737.x.
26. Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y, et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood. 2003;102:4236–42. doi:10.1182/blood-2002-10-3289.
27. Morishima Y, Sasazuki K, Inoko H, Juji T, Akaza T, Yamamoto K, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200–6. doi:10.1182/blood.V99.11.4200.
28. Kitawaki T, Kadowaki N, Ishikawa T, Ichinohe T, Uchiyama T. Compromised recovery of natural interferon-α/β-producing cells after allogeneic hematopoietic stem cell transplantation complicated by acute graft-versus-host disease and glucocorticoid administration. Bone Marrow Transplant. 2003;32:187–94. doi:10.1038/sj.bmt.1704093.
29. Saito T, Yoshioka S, Iinuma Y, Takakura S, Fujihara N, Ichinohe T, et al. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology–oncology unit. Eur J Clin Microbiol Infect Dis. 2008;27:209–16. doi:10.1007/s10096-007-0428-8.
30. Gooley TA, Leisenring W, Crowley JA, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med. 1999;18:665–706. doi:10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O.
31. Körbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood. 2001;98:2900–8. doi:10.1182/blood.V98.10.2900.
32. Dey BR, Shaffer J, Yee AJ, McAfee S, Caron M, Power K, et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2007;40:19–27. doi:10.1038/sj.bmt.1705688.
33. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048–54.
34. Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, et al. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Biol Blood Marrow Transplant. 2007;13:790–805. doi:10.1016/j.bbmt.2007.03.002.
35. Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, et al. Chronic graft-versus-host-disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol. 2007;137:142–51. doi:10.1111/j.1365-2141.2007.06543.x.
36. Hambach L, Stadler M, Dammann E, Ganser A, Hertenstein B. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29:903–6. doi:10.1038/sj.bmt.1703583.
37. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant. 2002;30:287–95. doi:10.1038/sj.bmt.1703633.
38. Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmeier BM, Slattery JT, et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood. 2005;106:4381–8. doi:10.1182/blood-2005-06-2217.
39. Lange S, Mueller SC, Altmann S, Dahlhaus M, Drewelow B, Freund M, et al. Pharmacokinetics of oral mycopheolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2008;41:667–74. doi:10.1038/sj.bmt.1705958.
40. Jacobson P, Green K, Rogosheske J, Brunstein C, Ebeling B, DeFor T, et al. Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol. 2007;47:6–12. doi:10.1177/0091270006295064.
41. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119–28. doi:10.1097/00007691-200104000-00005.
42. Kagaya H, Miura M, Satoh S, Inoue K, Saito M, Inoue T, et al. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. J Clin Pharm Ther. 2008;33:193–201. doi:10.1111/j.1365-2710.2008.00906.x.

Leukemia (2009) 23, 1270–1277
© 2009 Macmillan Publishers Limited All rights reserved 0887-6924/09 $32.00
www.nature.com/leu

ORIGINAL ARTICLE

GATA-1 and GATA-2 binding to 3′ enhancer of *WT1* gene is essential for its transcription in acute leukemia and solid tumor cell lines

A Furuhata[1], M Murakami[1], H Ito[1], S Gao[1], K Yoshida[1], S Sobue[2], R Kikuchi[3], T Iwasaki[3], A Takagi[1], T Kojima[1], M Suzuki[4], A Abe[5], T Naoe[5] and T Murate[1]

[1]*Department of Medical Technology, Nagoya University Graduate School of Health Sciences, Nagoya, Japan;* [2]*Department of Pathology, College of Life and Health Sciences, Chubu University, Kasugai, Japan;* [3]*Department of Laboratory Medicine, Nagoya University School of Medicine, Nagoya, Japan;* [4]*Division of Molecular Carcinogenesis, Nagoya University Graduate School of Medicine, Nagoya, Japan and* [5]*Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan*

Although oncogenic functions and the clinical significance of Wilms tumor 1 (*WT1*) have been extensively studied in acute leukemia, the regulatory mechanism of its transcription still remains to be determined. We found a significant correlation among the amounts of *WT1*, *GATA-1* and *GATA-2* mRNAs from leukemia and solid tumor cell lines. Overexpression and small interfering RNA (siRNA) transfection experiments of *GATA-1* and *GATA-2* showed that these *GATA* transcription factors could induce WT1 expression. Promoter analysis showed that the 5′ promoter did not explain the different *WT1* mRNA levels between cell lines. The 3′ enhancer, especially the distal sites out of six putative GATA binding sites located within the region, but not the intron 3 enhancer, were essential for the *WT1* mRNA level. Electrophoretic mobility shift assay (EMSA) showed both GATA-1 and GATA-2 bound to these GATA sites. Besides acute leukemia cell lines, solid tumor cell lines including, TYK-nu-cPr also showed a high level of *WT1* mRNA. We showed that *GATA-2* expression is a determinant of *WT1* mRNA expression in both TYK-nu-cPr cells and HL60 cells without GATA-1 expression. Taken together, these results suggest that GATA-1 and/or GATA-2 binding to a GATA site of the 3′ enhancer of *WT1* played an important role in *WT1* gene expression.
Leukemia (2009) **23**, 1270–1277; doi:10.1038/leu.2009.13; published online 12 February 2009
Keywords: *WT1* message; GATA-1 and 2; 5′ promoter; 3′ enhancer; EMSA; CHIP assay

Introduction

Wilms tumor 1 (*WT1*) gene was isolated as a tumor suppressor gene responsible for Wilm's tumor, a kidney neoplasm of childhood. The gene product, WT1, represses the transcription of growth factors, growth factor receptors and other genes.[1–3] On the other hand, *WT1* has been regarded as an oncogene for leukemia and some solid tumors because high expression levels of *WT1* mRNA were observed in these diseases, and *in vivo* and *in vitro* studies showed the positive roles it plays in cell growth and transformation.[4–8] *WT1* mRNA is reportedly a good clinical marker for disease progression, diagnosis and detection of the minimal residual diseases of myelodysplastic syndromes and leukemia.[9–11] Thus, depending on the cells and situations expressing WT1, it displays both anti-oncogenic and oncogenic characters.[12] Despite the fact that the oncogenic functions of WT1 have been well documented, its gene-expression mechanism remains undetermined.

In the promoter analysis of *WT1* gene, Cohen *et al.*[13] reported the importance of Sp1 for mRNA expression, although the promoter region may not determine the tissue-specific manner of *WT1* expression.[13,14] Regarding this point, the 3′ enhancer located >50 kb downstream of the promoter was identified as increasing the basal transcription rate of the *WT1* promoter in the erythroleukemia cell line K562.[14] Subsequently, Wu *et al.*[15] showed that GATA-1 may bind to this enhancer, which is reported to be specific in hematopoietic cells.[16] To date, in addition to Sp1 and GATA-1, PAX2 and PAX8 are also reported to be the transcription factors that regulate *WT1* gene expression.[17–20] Dehbi *et al.*[17] reported the binding sites of PAX2 and PAX8 in the 5′ promoter of *WT1* gene. Zhang *et al.*[20] indicated the importance of the intron 3 enhancer of *WT1* gene, which was activated by GATA-1 and Myb.

These earlier results suggest that between the cells analyzed, the regulation of *WT1* gene expression might be complex and heterogeneous. Furthermore, it was not clear what the major determinant of *WT1* mRNA level is either in leukemia or in solid tumors. Although the GATA family has been shown to play critical roles in erythroid and other hematopoietic lineages,[21,22] GATA-1 expression is low in M3, M4 and M5 of acute myelogeneous leukemia,[23] in which WT1 expression has been observed. Therefore, GATA-1 might not be sufficient to maintain full *WT1* gene expression. For another transcription factor candidate, we focused on GATA-2, which is presented in cells at the early-differentiated stage of hematopoietic lineages. We examined the relationship between *WT1*, *GATA-1* and *GATA-2* mRNA from 20 leukemia cell lines and 26 acute leukemia bone marrows, as well as purified stem cell and progenitor cell fractions from two normal bone marrows. We also examined solid tumor cell lines with high *WT1* expressions. There are no reports describing the regulatory mechanism of *WT1* gene expression in these cell lines.

On the basis of our results, we discussed the functional relationship between Sp1 and *WT1* expression and that between GATA and *WT1* expression in leukemia cell lines and several solid tumor cell lines.

Materials and methods

Clinical samples and cell lines

After obtaining informed consent, bone marrow cells were collected from 23 acute myeloid leukemia (AML) patients and three ALL patients without Ph[1] chromosome. Normal control

Correspondence: Professor T Murate, Department of Medical Technology, Nagoya University Graduate School of Health Sciences, Daiko-minami, 1-1-20 Higashi-ku, Nagoya, Aichi 461-8673, Japan.
E-mail: murate@met.nagoya-u.ac.jp
Received 28 June 2008; revised 28 November 2008; accepted 19 December 2008; published online 12 February 2009